NICE guidelines state that some patients with ovarian, breast & prostate cancer should receive genomic testing for Homologous Recombination Deficiency to identify for PARP inhibitors treatment eligibility.

The South East Genomic Medicine Service has launched a new Homologous Recombination Deficiency (HRD) service for all NHS colleagues working within cancer across the South East.

Join our free online webinar on January 26th from midday – 1pm to find out more, and understand how to access testing for your patients.

Listen to the following experts

• Prof Agnieszka Michael MRCP PhD, medical oncology consultant at the Royal Surrey NHS Foundation Trust
• Dr Katya Mokretar DipRCPath PhD, clinical scientist at the Cancer Genetics lab at South East Genomic Medicine Service
• Sébastien Sauvage, scientist at OncoDNA

They’ll be sharing their knowledge and answering questions. Highlights include:

• Gain an understanding of the HRD send-away service and its specific requirements.
• Understand the HRD reports and how they differ to what was received previously.
• Open table discussion around all aspects of the new service.

Everyone is welcome. This will be particularly useful for anyone working with ovarian cancer patients including oncologists, cancer nurses histopathologists, and scientists.

Book your place here.